“I previously referenced 7% as a as a very kind of sustainable growth rate. I believe 7% is still the right target.”

In context

“r line is open. Travis Steed: Hey, Robert. Thanks for taking the question. I guess as we move into the second half of this year, investors are going to start looking more into next year. Just curious how you think about the Abbott portfolio in the next year if this is like kind of a year that sets up for better growth. You have got easier nutrition comps, expanding coverage in Libre. You talked about EP accelerating in the next year. Amulet 360 launching at the beginning of the year. Just curious at a high level how you kind of think about the Abbott portfolio in 2027 and its growth? Robert Ford: Sure. I mean, it is a little early to give exact guidance for 2027. But you know, listen. We have a, a target always of targeting high single digit growth, on the top, double digit on the bottom. I previously referenced 7% as a as a very kind of sustainable growth rate. I believe 7% is still the right target. Despite there being a much larger base today versus where we were several years ago. it is probably only I think I looked at this as only like 5 healthcare companies with sales over 30 billion that are growing at least 7%. So I think I think we have a differentiated portfolio here, a very resilient portfolio. And I think, as I said, the strategy here of what we have been doing over the last couple quarters to get us in back into that, into that, 7% top line growth rate. I think it is really driven, Travis, by looking at the portfolio and then the-- if I look at, you know, the 4 segments, again, I am not providing 2027 guidance, but when I look at you know, each 1 of them and their ranges, you know, nutrition, you know, has been a 2% to 4% grower, and I think that is probably, as we think”